Centre for Sight Medical Director presents the new OptiLight at ESCRS 2021

Centre for Sight Medical Director presented the new Lumenis OptiLight at ESCRS 2021, the first FDA-Approved IPL treatment by Lumenis. Used to treat dry eye disease, this new technology targets the meibomian gland and provides a precise and comfortable dry eye procedure for patients.

Lumenis is now the world’s largest medical device company for aesthetic and ophthalmic surgical application. We were honoured to have our Medical Director, Sheraz M. Daya, as a world-renowned guest speaker and key opinion leader speak at the European Society of Cataract and Refractive Surgeons Annual Meeting. In October this year, Mr Daya demonstrated the precision, effectiveness and ease of use of the OptiLight for the management of Dry Eye Disease, referring it to the “Rolls Royce of IPL”!

Dry Eye is a common disorder that causes dry, gritty, burning, tired eyes and fluctuating vision. OptiLight IPL provides a light based treatment that offers a multi factorial approach to treatment which will help Dry Eye sufferers regain their quality of life.